4D Molecular Therapeutics (NASDAQ:FDMT) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) from “hold” to “sell”, adding a bearish view despite broader analyst sentiment that remains more positive.
• Other analysts are still largely constructive on the stock: several firms have buy/outperform/overweight ratings, and MarketBeat shows an average rating of “Moderate Buy” with a consensus target price of $29.88.
• The company recently reported a smaller-than-expected quarterly loss and higher-than-expected revenue, but it continues to post negative earnings, margins, and return on equity, underscoring ongoing profitability challenges.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday.

A number of other equities analysts have also recently commented on FDMT. Royal Bank Of Canada raised their target price on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an "outperform" rating in a report on Thursday, March 19th. Chardan Capital restated a "buy" rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. The Goldman Sachs Group set a $33.00 target price on 4D Molecular Therapeutics in a report on Friday. Barclays began coverage on 4D Molecular Therapeutics in a report on Wednesday, January 28th. They set an "overweight" rating and a $33.00 target price for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a report on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, 4D Molecular Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $29.88.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock opened at $10.14 on Friday. The business has a 50-day moving average of $9.38 and a 200 day moving average of $9.49. 4D Molecular Therapeutics has a 12 month low of $3.00 and a 12 month high of $12.34. The stock has a market capitalization of $530.07 million, a price-to-earnings ratio of -3.95 and a beta of 2.77.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 37.26%. The firm had revenue of $3.05 million for the quarter, compared to analysts' expectations of $2.59 million. Equities research analysts anticipate that 4D Molecular Therapeutics will post -3.71 earnings per share for the current year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. boosted its stake in shares of 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company's stock valued at $42,399,000 after buying an additional 1,090,000 shares during the period. Janus Henderson Group PLC boosted its stake in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company's stock valued at $34,726,000 after buying an additional 2,882,508 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 4.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company's stock valued at $32,272,000 after buying an additional 174,489 shares during the period. State Street Corp boosted its stake in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company's stock valued at $20,167,000 after buying an additional 1,785,106 shares during the period. Finally, Armistice Capital LLC boosted its stake in shares of 4D Molecular Therapeutics by 76.6% in the 4th quarter. Armistice Capital LLC now owns 1,936,000 shares of the company's stock valued at $14,520,000 after buying an additional 840,000 shares during the period. Hedge funds and other institutional investors own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.